Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in Neoadjuvant BRAF Wild-Type Melanoma
NCT04248387Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jun 2019
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in Malignant Melanoma (MM), sponsored by Fudan University. Status: unknown.
02
Drugs
toripalimab
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT04248387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04248387.